• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the July 15, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
FDA Briefing Information, (NDA) 22–580, proposed tradename, QNEXA (phentermine/topiramate) Controlled Release Capsules, for the July 15, 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 4.02MB)
 
 
VIVUS, Inc.
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
VIVUS, Inc. Briefing Information, (NDA) 22–580, proposed tradename, QNEXA (phentermine/topiramate) Controlled Release Capsules, for the July 15, 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF – 3.77MB)